ES2072223A1 - Liposomas encapsulando doxorubicina. - Google Patents

Liposomas encapsulando doxorubicina.

Info

Publication number
ES2072223A1
ES2072223A1 ES09302481A ES9302481A ES2072223A1 ES 2072223 A1 ES2072223 A1 ES 2072223A1 ES 09302481 A ES09302481 A ES 09302481A ES 9302481 A ES9302481 A ES 9302481A ES 2072223 A1 ES2072223 A1 ES 2072223A1
Authority
ES
Spain
Prior art keywords
doxorubicine
liposomes encapsulating
liposomes
cf3ch2o
ch3o
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09302481A
Other languages
English (en)
Other versions
ES2072223B1 (es
Inventor
Lambiez Fernando Pons
Gonzalez Raquel Delgado
Duena Antonio Parente
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to ES09302481A priority Critical patent/ES2072223B1/es
Priority to US08/346,236 priority patent/US5605703A/en
Priority to EP94500197A priority patent/EP0655239B1/en
Priority to AT94500197T priority patent/ATE183081T1/de
Priority to JP51485695A priority patent/JP4256930B2/ja
Priority to DE69420012T priority patent/DE69420012T2/de
Priority to PCT/ES1994/000127 priority patent/WO1995014459A1/es
Priority to DK94500197T priority patent/DK0655239T3/da
Publication of ES2072223A1 publication Critical patent/ES2072223A1/es
Application granted granted Critical
Publication of ES2072223B1 publication Critical patent/ES2072223B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LIPOSOMAS ENCAPSULANDO DOXORUBICINA, QUE CONTIENEN, INCORPORANDO EN LOS MISMOS, UN COMPUESTO PROTECTOR DE FORMULA GENERAL A O B, PARA REDUCIR LA TOXICIDAD DEL FARMACO CUANDO SE ADMINISTRA DE FORMA INTRAVENOSA, Y EN CUYAS FORMULAS: R1 Y R2, IGUALES O DIFERENTES REPRESENTAN INDEPENDIENTEMENTE HO-, CH3O- O CF3CH2O. LA RELACION ENTRE LOS LIPIDOS FORMADORES DE LOS LIPOSOMAS (TALES COMO FOSFOLIPIDOS Y COLESTEROL) Y EL FARMACO (DOXORUBICINA) ES DE 20:1 A 2:1 Y LA CANTIDAD PRESENTE DEL COMPUESTO PROTECTOR (INHIBIDOR DE LA PEROXIDACION LIPIDA) CON RESPECTO AL TOTAL DE LIPIDOS ES DEL ORDEN DE 0,01 A 15 POR CIENTO. LOS LIPOSOMAS SON DE APLICACION EN EL TRATAMIENTO DE NEOPLASMAS HUMANOS.
ES09302481A 1993-11-25 1993-11-25 Liposomas encapsulando doxorubicina. Expired - Fee Related ES2072223B1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES09302481A ES2072223B1 (es) 1993-11-25 1993-11-25 Liposomas encapsulando doxorubicina.
US08/346,236 US5605703A (en) 1993-11-25 1994-11-23 Liposomes encapsulating doxorubicin
AT94500197T ATE183081T1 (de) 1993-11-25 1994-11-25 Doxorubicine enkapsulierende liposomen
JP51485695A JP4256930B2 (ja) 1993-11-25 1994-11-25 ドキソルビシンを被包するリポソーム
EP94500197A EP0655239B1 (en) 1993-11-25 1994-11-25 Liposomes encapsulating doxorubicine
DE69420012T DE69420012T2 (de) 1993-11-25 1994-11-25 Doxorubicine enkapsulierende Liposomen
PCT/ES1994/000127 WO1995014459A1 (es) 1993-11-25 1994-11-25 Liposomas encapsulando doxorubicina
DK94500197T DK0655239T3 (da) 1993-11-25 1994-11-25 Liposom-indkapslet doxorubicin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09302481A ES2072223B1 (es) 1993-11-25 1993-11-25 Liposomas encapsulando doxorubicina.

Publications (2)

Publication Number Publication Date
ES2072223A1 true ES2072223A1 (es) 1995-07-01
ES2072223B1 ES2072223B1 (es) 1996-03-16

Family

ID=8283745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09302481A Expired - Fee Related ES2072223B1 (es) 1993-11-25 1993-11-25 Liposomas encapsulando doxorubicina.

Country Status (8)

Country Link
US (1) US5605703A (es)
EP (1) EP0655239B1 (es)
JP (1) JP4256930B2 (es)
AT (1) ATE183081T1 (es)
DE (1) DE69420012T2 (es)
DK (1) DK0655239T3 (es)
ES (1) ES2072223B1 (es)
WO (1) WO1995014459A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154560B1 (es) * 1998-09-16 2001-12-01 Lipotec Sa Composicion a base de derivados de cromanos y su uso para reducir quimicamente las reacciones oxidativas o inducidas por radicales libres.
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
FR2808189B1 (fr) * 2000-04-28 2004-03-05 Oreal Lipochroman-6 comme inhibiteur de no-synthase et utilisations
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US7029695B2 (en) * 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
AU2002361812B2 (en) * 2001-12-19 2007-11-08 Research Development Foundation Liposomal delivery of vitamin E based compounds
US20050058698A1 (en) * 2002-01-21 2005-03-17 Nolan Yvonne Mairead Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
DE10259014A1 (de) 2002-12-16 2004-06-24 Henkel Kgaa Antioxidans-Kombinationen mit6,7-disubstituierten 2,2-Dialkylchromanen oder-chromenen
US20050009772A1 (en) * 2003-05-06 2005-01-13 The Regents Of The University Of California Methods and compositions for the treatment of glaucoma and other retinal diseases
JP2008507282A (ja) 2004-07-20 2008-03-13 アイソジェニス・インコーポレイテッド 自己免疫および自己抗原に関連する疾患の特異的阻害
US7470672B2 (en) 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
DE102006062501A1 (de) 2006-12-28 2008-07-03 Henkel Kgaa Kosmetische und dermatologische Öl-in-Wasser-Emulsionen mit selbstkonservierenden Eigenschaften
ES2310142B1 (es) * 2007-06-15 2009-12-04 Lipotec S.A Compuestos reguladores de la pigmentacion.
US8524783B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
DE102009026414A1 (de) 2009-05-22 2010-11-25 Henkel Ag & Co. Kgaa Hautbehandlung zur Porenverfeinerung
WO2011135905A1 (ja) * 2010-04-28 2011-11-03 国立大学法人北海道大学 脂質膜構造体
CN103083239B (zh) 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000968A1 (en) * 1983-09-06 1985-03-14 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
WO1987004592A1 (en) * 1986-02-10 1987-08-13 Liposome Technology, Inc. Controlled-release liposome delivery system
WO1988009168A1 (en) * 1987-05-18 1988-12-01 Liposome Technology, Inc. Liposome/doxorubicin composition and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
CA2088975A1 (en) * 1990-08-08 1992-02-09 Anthony H. Huang Stable doxorubicin/liposome composition
CA2055990A1 (en) * 1990-11-22 1992-05-23 David G. Schena Phospholipid-vitamin derivatives and methods for preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000968A1 (en) * 1983-09-06 1985-03-14 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
WO1987004592A1 (en) * 1986-02-10 1987-08-13 Liposome Technology, Inc. Controlled-release liposome delivery system
WO1988009168A1 (en) * 1987-05-18 1988-12-01 Liposome Technology, Inc. Liposome/doxorubicin composition and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOSEFINA CASAS et al. Inhibition of Rat Liver Microsomal Lipid Peroxidation Elicited by Simple 2,2-Dimetrylchromenes and Chromans Structurally Related to Precavenes. J. Agric. Food Chem. 1992, 40, 585-590 *
JOSEP IRURRE et al. Inhibition of Rat Liver Microsomal Lipid Peroxidation Elicited by 2,2-Dimetrylchromenes and Chromans Containing Fluorinated Moieties Resistant to Cytochroma P-450 Metabolism Bioorganic y Medicinal Chemistry Vol. 1, N‘ 3, Pßg. 219-225, 1993. *

Also Published As

Publication number Publication date
US5605703A (en) 1997-02-25
EP0655239A1 (en) 1995-05-31
JPH08506124A (ja) 1996-07-02
DK0655239T3 (da) 2000-03-20
DE69420012T2 (de) 2000-03-23
ES2072223B1 (es) 1996-03-16
ATE183081T1 (de) 1999-08-15
WO1995014459A1 (es) 1995-06-01
DE69420012D1 (de) 1999-09-16
EP0655239B1 (en) 1999-08-11
JP4256930B2 (ja) 2009-04-22

Similar Documents

Publication Publication Date Title
ATE183081T1 (de) Doxorubicine enkapsulierende liposomen
GEP20002210B (en) Acridine Derivatives
GEP20012390B (en) Benzonaphthyridines as Bronchial Therapeutics
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
MY105328A (en) Blocking agents of edrf effect or formation for the treatment of shock.
GEP20032957B (en) Nonpeptidyl Compositions
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
GEP20001968B (en) Arilthio Compounds as Antibacterial and Antiviral Agents
GR3022631T3 (en) Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
AU1200695A (en) 4,5-diaryloxazole derivatives
AU1614492A (en) New peptide compound and a process for the preparation thereof
EP0765865A4 (en) 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION
GEP20032953B (en) Antitumor Agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
GEP20053617B (en) Bridged Piperazine Derivatives
IL110460A0 (en) Bis-naphthalimides and pharmaceutical compositions containing them
IE892596L (en) Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties
GB1515241A (en) Beta-lactam antibiotics
AU8226891A (en) Benzopyran derivative, production thereof, and pharmaceutical composition containing the same
GEP20043225B (en) 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives
AU639875B2 (en) 5-amino-5,6,7,8-tetrahydroquinolines and related compounds and pharmaceutical use
EP0598117A4 (en) BENZOPYRAN DERIVATIVE AND ANTI-ALLERGIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT.
MY131278A (en) Octahydrobenzo [g] quinoline
AU1287892A (en) Method of inhibiting the progressive development of diabetes mellitus

Legal Events

Date Code Title Description
PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20180806